- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02487173
Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B
A Prospective Multi-Centre Study of the Respirio Flu Test Performance Versus Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and Sofia® Influenza A+B Fluorescent Immunoassay (FIA) for the Rapid Detection of Influenza A/B
The primary purpose of this study is to validate the sensitivity and specificity of the Respirio Flu Test in detecting Influenza A, when used by subjects, as compared to the gold standard for detection, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).
The secondary aims are to:
- validate the sensitivity and specificity of the Respirio Flu Test in detecting Influenza B , when used by subjects, as compared to the gold standard for detection, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).
- assess agreement (positive and negative) between Respirio Flu Test and Sofia® Influenza A+B Test in detecting Influenza A;
- assess agreement (positive and negative) between Respirio Flu Test and Sofia® Influenza A+B Test in detecting Influenza B;
- evaluate the correct interpretation of the Respirio Flu Test results by subjects with Influenza-like illness symptoms;
- evaluate the subjects' satisfaction with the convenience, comfort and ease of use of the Respirio Flu Test;
- evaluate the subjects' comprehension of the Respirio Flu Test labelling; and
- establish the minimum sample weight required to achieve a result with the Respirio Flu Test.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Queensland
-
Brisbane, Queensland, Australia, 4068
- Taringa 7 Day Medical Practice
-
Brisbane, Queensland, Australia, 4075
- Graceville Medical
-
Brisbane, Queensland, Australia, 4077
- Inala Primary Care
-
Ipswich, Queensland, Australia, 4305
- Limestone Medical Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects aged ≥ 1 year;
- Rhinorrhea;
- ≤ 72 hours from onset of Influenza-like illness symptoms;
- Subject (or parent/legal guardian) capable and willing to give informed consent/assent.
- Subject (or parent/legal guardian) able to read and write in English.
Exclusion Criteria:
- Has undergone treatment with antivirals within the previous 7 days;
- Has been vaccinated by means of an Influenza nasal spray/mist vaccine within the previous 7 days;
- Recent craniofacial injury or surgery, including surgery to correct deviation of the nasal septum, within the previous 6 months;
- Currently enrolled in another clinical trial or used any investigational device within 90 days preceding informed consent;
- Has had prior exposure to the Respirio Flu Test;
- Subject (or parent/legal guardian) residing at the same residential address as a subject currently enrolled in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Respirio Flu Test
Upper respiratory tract samples from participants will be tested with:
|
The Respirio Flu Test is a rapid test for the detection of influenza A or influenza B in nasal secretions.
The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates.
The reverse-transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
Sofia® Influenza A+B Fluorescent Immunoassay (FIA) employs immunofluorescence to detect influenza A and influenza B viral nucleoprotein antigens in nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash samples taken directly from symptomatic patients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Of participants positive for influenza A by ReverseTranscriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza A by Respirio Flu Test.
Time Frame: Day 1
|
Establish sensitivity against a gold standard.
Report as a percentage of participants with 95% confidence limits.
|
Day 1
|
Of participants negative for influenza A by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza A by Respirio Flu Test.
Time Frame: Day 1
|
Establish specificity against a gold standard.
Report as a percentage of participants with 95% confidence limits.
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of participants who correctly interpret result of Respirio Flu Test.
Time Frame: Day 1
|
Agreement between trained staff and participants.
Report as a percentage of participants with 95% confidence limits.
|
Day 1
|
Of participants positive for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza B by Respirio Flu Test.
Time Frame: Day 1
|
Establish sensitivity against a gold standard.
Report as a percentage of participants with 95% confidence limits.
|
Day 1
|
Of participants negative for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza B by Respirio Flu Test.
Time Frame: Day 1
|
Establish specificity against a gold standard.
Report as a percentage of participants with 95% confidence limits.
|
Day 1
|
Percent of participants positive for influenza A by Sofia® Influenza A+B Test and Respirio Flu Test.
Time Frame: Day 1
|
Establish positive agreement against an imperfect standard.
Report as a percentage of participants with 95% confidence limits.
|
Day 1
|
Percent of participants negative for influenza B by Sofia® Influenza A+B Test and Respirio Flu Test.
Time Frame: Day 1
|
Establish negative agreement against an imperfect standard.
Report as a percentage of participants with 95% confidence limits.
|
Day 1
|
Combine positive and negative agreement of Respirio Flu Test and Sofia® Influenza A+B Test to establish overall agreement. Report as a percentage of participants with 95% confidence limits.
Time Frame: Day 1
|
Day 1
|
|
Scores from questionnaire to assess ease of use, comfort and convenience of Respirio Flu Test.
Time Frame: Day 1
|
The ease of use questionnaire will provide the following: • Total number of responses to each question and the percentage of participants selecting each response (most on a 5 point Likert scale). |
Day 1
|
Percent of participants correctly determining eligibility and conditions for use of Respirio Flu Test from scores on a label comprehension questionnaire.
Time Frame: Day 1
|
The label comprehension questionnaire will provide the following data
|
Day 1
|
Weight of sample deposited in Respirio Flu Test.
Time Frame: Day 1
|
Establish minimum weight of sample required to obtain a valid result from the Respirio Flu Test.
|
Day 1
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RESP15001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza A
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | Orthomyxoviridae | H5N1 VirusUnited States
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | H5N1 Virus | OrthomyxovirdaeUnited States
-
Emergent BioSolutionsCompletedInfluenza A H3N2 | Influenza A H1N1United States, Spain, Canada, Puerto Rico
-
Butantan InstituteUniversity of Sao Paulo; Insituto Adolfo Lutz; Centro de Referencia e Treinamento...CompletedImmunocompromised Patients | Safety of Pandemic Influenza A (H1N1)Vaccine | Immunogenicity of Pandemic Influenza A (H1N1)VaccineBrazil
-
Novartis VaccinesCompletedNovel Influenza A (H1N1) | A New Flu Virus of Swine OriginChile, Colombia, Germany, Switzerland
-
Novartis VaccinesCompletedA New Flu Virus of Swine Origin | Pandemic Influenza A (H1N1)Argentina, Netherlands
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
-
National Institute of Allergy and Infectious Diseases...University of Minnesota; International Network for Strategic Initiatives in...CompletedInfluenza A | Influenza BUnited States, Australia, Denmark, United Kingdom
Clinical Trials on Respirio Flu Test
-
Ellume Pty LtdCompletedInfluenza A | Influenza BAustralia
-
Respirio Pty LtdCompleted
-
Groupe Hospitalier Paris Saint JosephCompleted
-
EDAN Instruments Inc.MDx CRO (MED IVD HEALTHTECH S.L.)RecruitingSARS-CoV2 Infection | Influenza A | Respiratory Syncytial Virus (RSV) | Influenza BSpain
-
Lucira Health IncCompleted
-
Ellume Pty LtdCompleted
-
Ellume Pty LtdCompleted
-
Aptitude Medical SystemsBiomedical Advanced Research and Development AuthorityRecruitingSARS-CoV-2 Infection | Influenza A | Influenza BUnited States
-
Sequenom, Inc.Labcorp Corporation of America Holdings, IncRecruitingInfluenza A | RSV Infection | COVID-19 Respiratory Infection | Influenza Type BUnited States
-
Medical Group Care, LLCCSSi Life SciencesCompletedCOVID-19 | Influenza A | Influenza BUnited States